Skip to content

Clinical efficacy and safety of tibia transverse transport in treatment of severe diabetic foot: a prospective, multicenter, randomized, parallel controlled clinical study

Clinical efficacy and safety of tibia transverse transport in treatment of severe diabetic foot: a prospective, multicenter, randomized, parallel controlled clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081183
Enrollment
Unknown
Registered
2024-02-26
Start date
2024-03-01
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic foot ulcers

Interventions

control group:Debridement dressing
intervention group:Tibial transverse transport

Sponsors

the First affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age =18 years old; 2. Meet the diagnostic criteria for diabetes: fasting blood glucose = 7.0 mmol/L or oral glucose tolerance test or 2 hours after meals blood glucose >11.1mmol/L or hemoglobin a1C (HbA1c) = 6.5%; 3. Patients with severe diabetic foot, i.e. Texas Scale ?-? (ulcer involving tendon, joint capsule, bone, or joint cavity); 4. The ulcer site is far from the ankle joint, the initial onset or recurrence can be; 5. Ulcer area =10cm^2; 6. Volunteer to participate in the study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. In the past 3 months, there were new serious cardiovascular and cerebrovascular adverse events, such as heart failure, myocardial infarction, severe arrhythmia, stroke, etc. 2. Patients with end-stage renal disease received blood purification therapy or serum creatinine clearance <30ml/min/ 1.73m^2 for a long time; 3. Advanced cancer or other end-stage diseases with an expected survival of less than 1 year; 4. Currently receiving cytotoxic drugs, glucocorticoids or other immunosuppressants, or receiving chemoradiotherapy; 5. Coagulation dysfunction or poor general general condition, unable to tolerate anesthesia and surgery; 6. Combined with Charcot arthropathy of the foot; 7. Severe peripheral vascular disease, popliteal artery stenosis = 70%; 8. There is a soft tissue infection or tumor in the operative site of the tibia, which cannot be operated on. 9. History of revascularization (endovascular therapy, reconstruction, or bridging) in the affected limb within the last 3 months; 10. Pregnancy or lactation; 11. Combined with mental disorders, unable to cooperate with treatment; 12. Who are participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Ulcer healing rate at the sixth months;

Secondary

MeasureTime frame
Ulcer healing rate at the twelveh months;Amputation rate;Ulcer recurrence rate;Changes of lower extremity microvessels;Blood flow and blood volume in ulcerated foot muscles;Ankle-brachial pressure index;Foot pain;Foot sensation;Foot function;

Countries

China

Contacts

Public ContactHua Qikai

the First Affiliated Hospital of Guangxi Medical University

hqk100@yeah.net+86 151 7712 5661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026